Clinical significance of antinuclear antibodies and other serological abnormalities in systemic lupus erythematosus (SLE)
Novak, S.
Reumatizam 56(2): 22-25
2009
ISSN/ISBN: 0374-1338 PMID: 20429257 Document Number: 631886
Antinuclear antibodies are main serologic halmark of SLE. Some of them are patogenic. Others are epiphenomenon. Clinical significance of some antibodies are important in making dyagnosis of the disease, others are more importnat in monitoring the disease. Some antibodies are in correlation with particular clinical signs of the diseases.
Document emailed within 1 workday
Related Documents
Guzman, L.; Avalos, E.; Ortiz, R.; Gurrola, R.; Lopez, E.; Herrera, R. 1987: Placental abnormalities in systemic lupus erythematosus: in situ deposition of antinuclear antibodies Journal of Rheumatology 14(5): 924-929Xie, H.; Liu, Z.; Zhu, W. 1997: Significance of antinuclear antibodies for the diagnosis and activity of systemic lupus erythematosus Hunan Yi Ke Da Xue Xue Bao 22(2): 177-178
Aho, K.; Koskela, P.; Mäkitalo, R.; Heliövaara, M.; Palosuo, T. 1992: Antinuclear antibodies heralding the onset of systemic lupus erythematosus Journal of Rheumatology 19(9): 1377-1379
Monegat, J.N.; Joller-Jemelka, H.I.; Grob, P.J. 1974: Antinuclear antibodies and beta1A concentration in systemic lupus erythematosus and other diseases Schweizerische Medizinische Wochenschrift 104(45): 1614-1623
Smolen, J.S.; Hassfeld, W.; Graninger, W.; Steiner, G. 1990: Antibodies to antinuclear subsets in systemic lupus erythematosus and rheumatoid arthritis Clinical and Experimental Rheumatology 8(Suppl 5): 41-44
Meyer, O.; Molta, C.; Bourgeois, P.; Haim, T.; Kahn, M.F. 1990: Profile of antinuclear antibodies in 14 cases of extinct systemic lupus erythematosus for more than 3 years Revue du Rhumatisme et des Maladies Osteo-Articulaires 57(9): 599-603
Nakano, M.; Ohuchi, Y.; Hasegawa, H.; Kuroda, T.; Ito, S.; Gejyo, F. 2000: Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus Journal of Rheumatology 27(6): 1403-1407
Pigrau, A.; Martínez-Vázquez, J.M.; Bacardí, R.; Ocanña, I.; Pahissa, A. 1984: Complement binding anti-DNA antibodies: its clinical significance in systemic lupus erythematosus Medicina Clinica 83(19): 787-791
Parker, M.D. 1973: Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease Journal of Laboratory and Clinical Medicine 82(5): 769-775
Falcao, C.A.; Alves, I.C.; Chahade, W.H.; Duarte, A.L.B.P.; Lucena-Silva, N. 2002: Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus Arquivos Brasileiros de Cardiologia 79(3): 285-291
Galeazzi, M.; Annunziata, P.; Sebastiani, G.D.; Bellisai, F.; Campanella, V.; Ferrara, G.B.; Font, J.; Houssiau, F.; Passiu, G.; De Ramon Garrido, E.; Fernandez-Nebro, A.; Bracci, L.; Scorza, R.; Puddu, P.; Jedryka-Goral, A.; Smolen, J.; Tincani, A.; Carcassi, C.; Morozzi, G.; Marcolongo, R. 2000: Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE Journal of Rheumatology 27(1): 135-141
O'Neill, T.W.; Mahmoud, A.; Tooke, A.; Thomas, R.D.; Maddison, P.J. 1993: Is there a relationship between subclinical myocardial abnormalities, conduction defects and Ro/la antibodies in adults with systemic lupus erythematosus? Clinical and Experimental Rheumatology 11(4): 409-412
Dubois, E.L.; Chandor, S.; Friou, G.J.; Bischel, M. 1971: Progressive systemic sclerosis and localized scleroderma morphea with positive lupus erythematosus cell test and unusual systemic manifestations compatible with systemic lupus erythematosus presentation of 14 cases including 1 set of identical twins 1 with scleroderma and the other with systemic lupus erythematosus review of the literature Medicine (Baltimore) 50(3): 199-222
Rauch, J.; Hazeltine, M.; Tannenbaum, H.; Danoff, D.; Isenberg, D.A.; Wild, J.; Sampalis, J.; Esdaile, J.M. 1990: Association of anti-DNA idiotype markers with clinical and serological manifestations in patients with systemic lupus erythematosus Journal of Rheumatology 17(2): 178-185
Duc, J.; Perroulaz, G.; Golaz, J.; Campiche, M.; Pécoud, A. 1987: Disseminated lupus erythematosus without antinuclear antibodies or other autoantibodies Schweizerische Medizinische Wochenschrift 117(6): 205-208
Gladman, D.D.; Chalmers, A.; Urowitz, M.B. 1978: Systemic lupus erythematosus with negative LE cells and antinuclear factor Journal of Rheumatology 5(2): 142-147
Aho, K.; Koskela, P.; Mäkitalo, R.; Heliövaara, M.; Palosuo, T. 1992: Do antinuclear antibodies precede systemic lupus? Duodecim; Laaketieteellinen Aikakauskirja 108(2): 157-160
Hara, M. 1977: Clinical significance of the lymphocyte function in systemic lupus erythematosus Ryumachi 17(1): 6-16
Tsebetsauér, L.; Poverennyĭ, A.I.; Nasonov, E.L.; Podgorodnichenko, V.K.; Korogodin, D.V. 1987: Clinical value of determining the anti-DNA antibodies with different avidities in systemic lupus erythematosus Terapevticheskii Arkhiv 59(4): 48-50
Blaustein, D.A.; Blaustein, S.A. 1998: Antinuclear antibody negative systemic lupus erythematosus presenting as bilateral facial paralysis Journal of Rheumatology 25(4): 798-800